LB Pharmaceuticals Speeds Up Phase 3 LB-102 Trial, Topline Results Now Expected In Early 2027

LB Pharmaceuticals Inc., a neuromedicines company focused on developing and commercializing innovative therapies for serious brain disorders with limited treatment options, has announced an updated development timeline for its lead drug candidate, LB-102. Driven by stronger-than-expected patient enrollment, the Company now anticipates reporting topline results from its pivotal Phase 3 NOVA-2 clinical trial in the first half of 2027, earlier than its previous projection of the second half of 2027. 

Following the release of these results, LB Pharmaceuticals plans to schedule a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA) during the second half of 2027 as it advances the regulatory process. The NOVA-2 study is a pivotal Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of LB-102 as a treatment for patients with schizophrenia. The study is expected to enroll approximately 460 participants across 25 clinical sites in the United States, providing a broad evaluation of the therapy's effectiveness and safety profile.

According to Heather Turner, Chief Executive Officer of LB Pharmaceuticals, patient enrollment in the NOVA-2 trial has progressed at a faster pace than originally expected. She stated that the accelerated recruitment reflects both the Company's efficient execution of the clinical program and the growing interest in LB-102 as a potential new treatment option for schizophrenia. Based on the steady enrollment rate since the trial began, the Company has been able to advance its expected timeline for reporting topline data, bringing it forward by several months compared to earlier guidance.

Turner also emphasized the Company's strong financial position, noting that LB Pharmaceuticals remains well capitalized, with available cash expected to support operations into the second quarter of 2029. This financial runway is projected to cover multiple important clinical milestones beyond the Phase 3 schizophrenia program. 

These include topline results from the Phase 2 ILLUMINATE-1 trial evaluating LB-102 in patients with bipolar depression, which are expected in the first quarter of 2028, followed by topline data from a Phase 2 study assessing LB-102 as an adjunctive treatment for major depressive disorder (MDD) in the first half of 2029. The Company believes this financial stability will allow it to continue advancing its clinical development pipeline while preparing for future regulatory submissions.